[1] Broyles AD, Banerji A, Castells M. Practical guidelines for the evaluation and management of drug hypersensitivity: general concepts[J].J Allergy Clin Immunol Practice,2020, 8(9):S3-S15.
[2] 李全生, 朱晓明, 魏庆宇. 2014药物过敏的国际共识解读; 第七次全国中西医结合变态反应学术会议、辽宁省首届中西医结合变态反应学术会议、沈阳军区首届免疫学及变态反应学术会议[C].中国辽宁沈阳, F, 2015.
[3] Warrington R, Watson W, Kim H, et al. An introduction to immunology and immunopathology[J].Allergy Asthma Clin Immunol,2018,14(Suppl 2):49.
[4] 曹雪涛. 医学免疫学[M]. 人民卫生出版社, 2018.
[5] MALAK. Type Ⅰ Hypersensitivity Reaction [M].Treasure Island (FL):StatPearls Publishing,2020.
[6] AA. Immediate Hypersensitivity Reactions [M].Treasure Island (FL):StatPearls Publishing,2020.
[7] NORINA. Type Ⅲ Hypersensitivity Reaction [M]. Treasure Island (FL):StatPearls Publishing,2020.
[8] KHALED. Type Ⅳ Hypersensitivity Reaction [M]. Treasure Island (FL):StatPearls Publishing,2020.
[9] Zaccara G, Franciotta D, PERUCCA E. Idiosyncratic adverse reactions to antiepileptic drugs[J].Epilepsia, 2007, 48(7): 1223-1244.
[10] Handoko K, Van Puijenbroek E, Bijl A, et al. Influence of chemical structure on hypersensitivity reactions induced by antiepileptic drugs: the role of the aromatic ring [J].Drug safety,2008, 31(8): 695-702.
[11] Karimzadeh P, Bakrani V. Antiepileptic drug-related adverse reactions and factors influencing these reactions [J].Iran J Child Neurol,2013, 7(3): 25-29.
[12] Kuyucu S, Caubet J. Hypersensitivity Reactions to Antiepileptic Drugs in Children: Epidemiologic, Pathogenetic, Clinical, and Diagnostic Aspects [J].J Allergy Clin Immunol Pract,2018, 6(6): 1879-1891.
[13] Demir S, Erdenen F, Gelincik A, et al. Evaluation of the Potential Risk Factors for Drug-Induced Anaphylaxis in Adult Patients [J].Int Arch Allergy Iimmunol,2019, 178(2): 167-176.
[14] Kurt E, Demir A, Cadirci O, et al. Immediate-type drug hypersensitivity and associated factors in a general population [J].Allergol Iimmunopathol,2011, 39(1): 27-31.
[15] Foer D, Bucheit K, Gargiulo A, et al. Progestogen Hypersensitivity in 24 Cases: Diagnosis, Management, and Proposed Renaming and Classification [J].J Allergy Clin Immunol Pract,2016, 4(4): 723-729.
[16] Motosue M, Bellolio M, Van Houten H, et al. Risk factors for severe anaphylaxis in the United States [J].Ann Allergy Asthma Immunol,2017, 119(4): 356-361.
[17] Worm M, Francuzik W, Renaudin J, et al. Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry [J].Allergy,2018, 73(6): 1322-1330.
[18] Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example [J].Mol Diag Ther,2009, 13(1): 1-9.
[19] Phillips E, Wong G, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity [J].AIDS (London, England),2005, 19(9): 979-981.
[20] Regateiro F, Marques M, Gomes E. Drug-Induced Anaphylaxis: An Update on Epidemiology and Risk Factors [J].Int Arch Allergy Immunol,2020, 181(7): 481-487.
[21] Kurt E, Demir A, Cadirci O. Immediate type drug hypersensitivity reactions and associated risk factors in an adult Turkish men population [J].Iran J Allergy Asthma Immunol,2010, 9(4): 245-250.
[22] Snchez-orges M, Capriles-hulett A. Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity [J].Ann Allergy Asthma Immunol,2000, 84(1): 101-106.
[23] Schwartz L, Metcalfe D, Miller J, et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis [J].N Engl J Med,1987, 316(26): 1622-1626. |
2021, Vol. 38 
